The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Datar Cancer Genetics’ new blood test, TriNetra-Glio, intended to help diagnose inaccessible brain tumours.

Using 15ml blood, the new liquid biopsy has been designed to diagnose brain tumours in cases where a conventional biopsy is not possible.

It is indicated for patients who require a brain biopsy, which either cannot be performed or has already been unsuccessful.

The TriNetra-Glio test is developed for identifying extremely rare cells that are released into the blood by a brain tumour.

A research team at Imperial College, London, UK, conducted a blinded, prospective study on the new liquid biopsy.

In the study, the TriNetra-Glio liquid biopsy showed high accuracy in detecting brain tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Datar Cancer Genetics medical director Dr Darshana Patil said: “The breakthrough designation by the FDA is a landmark recognition of the technology behind the test.

“Our proprietary CTC-enrichment and detection technology powers the non-invasive test to help diagnose challenging cases of brain tumours without any attendant risk. The test has previously received CE certification in Europe.”

The company stated that TriNetra-Glio is its third diagnostic test to receive Breakthrough Device Designation from the US FDA.

It previously secured FDA Breakthrough Device Designations for its tests for early-stage detection of breast and prostate cancers.

According to Datar, diagnosis of brain tumours is risky and requires lots of resources. Furthermore, brain biopsies are difficult to perform in almost 40% of advanced cases.

Datar claimed that there is currently no blood test available for the diagnosis of brain cancers in the world, leaving doctors to depend on complex surgical procedures for histopathological evaluation of tumour tissue.